mRNA-Based Platform Shows Promise for Developing Vaccines

The new experimental mRNA platform fixed some issues with the industry standard platform, and could help fight infectious disease, cancer, and autoimmune conditions.

Key Highlights

  • The ac4C-modified mRNA platform nearly doubles the speed of ribosome movement compared to standard mRNA.
  • Enhanced translation efficiency may enable smaller doses of vaccines and therapeutics with stronger immune responses.
  • The study involved testing in human dendritic cells and mouse liver cells to mimic real-world vaccine applications.
  • ac4C modification reduces premature termination and frameshifting, leading to higher quality protein production.
  • This breakthrough could accelerate the development of vaccines for infectious diseases, cancer, and autoimmune conditions.

A study funded and co-led by the NIH and published in Nature reports that an experimental mRNA-based platform has the potential to aid in developing vaccines against infectious disease, cancer, and autoimmune conditions.

The study involved comparing an experimental mRNA platform with the industry standard mRNA platform. One of the study’s authors said that the experimental platform, ac4C, “causes cells to produce more therapeutic proteins to fight disease than the industry standard mRNA platform,” m1Ψ.

With m1Ψ as a delivery system, ribosomes that travel along single strands of mRNA containing the modification may slow down and cause traffic jams, which creates less protein that triggers an immune response. So, the scientists inserted both modifications into cultured human dendritic cells and mouse liver cells to mimic how vaccines work.

The researchers found that ribosomes traveled nearly twice as fast on the ac4C-modified mRNA. The m1Ψ platform also caused premature termination or frameshifting, making less or compromised proteins. The ac4C platform resulted in smoother mRNA translation. This could help scientists investigate potential therapeutics that require smaller doses while creating more protein and a better immune response.

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care. 

Sign up for our eNewsletters
Get the latest news and updates